CREBBP is a Major Prognostic Biomarker for Relapse in Childhood B-cell Acute Lymphoblastic Leukemia: A National Study of Unselected Cohort

1. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)-NCI. Available online: https://www.cancer. gov/types/leukemia/hp/child-all-treatment-pdq (accessed on 16.10.2024). Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)-NCI . Available online: https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq (accessed on 16.10.2024 ). Search in Google Scholar

2. SEER*Explorer Application. Available online: https://seer.cancer.gov/statistics-network/explorer/application.html?site=92&data_type=1&graph_ type=1&compareBy=sex&chk_sex_1=1&rate_ type=2&race=1&age_range=16&advopt_ precision=1&advopt_show_ci=on&hdn_ view=0&advopt_show_apc=on&advopt_ display=2#resultsRegion0 (accessed on 16.10.2024) SEER*Explorer Application . Available online: https://seer.cancer.gov/statistics-network/explorer/application.html?site=92&data_type=1&graph_type=1&compareBy=sex&chk_sex_1=1&rate_type=2&race=1&age_range=16&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0 (accessed on 16.10.2024 ) Search in Google Scholar

3. Forero RM, Hernández M, Hernández-Rivas JM. Genetics of Acute Lymphoblastic Leukemia. In Leukemia. Prof. Margarita Guenova (Ed.); IntechOpen: London, UK, 2013; doi:10.5772/55504 Forero RM Hernández M Hernández-Rivas JM. Genetics of Acute Lymphoblastic Leukemia . In Leukemia . Prof. Margarita Guenova (Ed.); IntechOpen : London, UK , 2013 ; doi: 10.5772/55504 Open DOISearch in Google Scholar

4. Studd JB, Cornish AJ, Hoang PH, Law P, Kinnersley B, Houlston R. Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes. Blood Cancer J. 2021;11(11):1-10. doi:10.1038/s41408-021-00570-9 Studd JB Cornish AJ Hoang PH Law P Kinnersley B Houlston R. Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes . Blood Cancer J . 2021 ; 11 ( 11 ): 1 - 10 . doi: 10.1038/s41408-021-00570-9 Open DOISearch in Google Scholar

5. Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology. 2012;2012(1):389-396. doi:10.1182/asheducation.V2012.1.389.3798360 Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia . Hematology . 2012 ; 2012 ( 1 ): 389 - 396 . doi: 10.1182/asheducation.V2012.1.389.3798360 Open DOISearch in Google Scholar

6. Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977-3987. doi:10.1182/blood-2015-02-580043 Hunger SP Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine . Blood . 2015 ; 125 ( 26 ): 3977 - 3987 . doi: 10.1182/blood-2015-02-580043 Open DOISearch in Google Scholar

7. Woo JS, Alberti MO, Tirado CA. Childhood B-acute lymphoblastic leukemia: a genetic update. Exp. hema-tol. oncol. 2014;3(1):16. doi:10.1186/2162-3619-3-16 Woo JS Alberti MO Tirado CA. Childhood B-acute lymphoblastic leukemia: a genetic update . Exp. hema-tol. oncol . 2014 ; 3 ( 1 ): 16 . doi: 10.1186/2162-3619-3-16 Open DOISearch in Google Scholar

8. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. The Lancet. 2013;381(9881):1943-1955. doi:10.1016/S0140-6736(12)62187-4 Inaba H Greaves M Mullighan CG. Acute lymphoblastic leukaemia . The Lancet . 2013 ; 381 ( 9881 ): 1943 - 1955 . doi: 10.1016/S0140-6736(12)62187-4 Open DOISearch in Google Scholar

9. Rob Pieters, Charles G. Mullighan, Stephen P. Hunger. Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL. J. Clin. Oncol. 2023;41:5579-5591. doi:10.1200/JCO.23.01286 Rob Pieters Charles G. Mullighan, Stephen P. Hunger. Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL . J. Clin. Oncol . 2023 ; 41 : 5579 - 5591 . doi: 10.1200/JCO.23.01286 Open DOISearch in Google Scholar

10. Chang TC, Chen W, Qu C, et al. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J. Clin. Oncol. 2024;42(29):3491-3503. doi:10.1200/JCO.23.02238 Chang TC Chen W Qu C Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia . J. Clin. Oncol . 2024 ; 42 ( 29 ): 3491 - 3503 . doi: 10.1200/JCO.23.02238 Open DOISearch in Google Scholar

11. Brady SW, Roberts KG, Gu Z, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54(9):1376-1389. doi:10.1038/s41588-022-01159-z Brady SW Roberts KG Gu Z The genomic landscape of pediatric acute lymphoblastic leukemia . Nat Genet . 2022 ; 54 ( 9 ): 1376 - 1389 . doi: 10.1038/s41588-022-01159-z Open DOISearch in Google Scholar

12. Morscio J, Van Vlierberghe P. Chemotherapy at the wheel of ALL relapse. Blood. 2020;135(1):4-5. doi:10.1182/blood.2019003870 Morscio J Van Vlierberghe P. Chemotherapy at the wheel of ALL relapse . Blood . 2020 ; 135 ( 1 ): 4 - 5 . doi: 10.1182/blood.2019003870 Open DOISearch in Google Scholar

13. Mullighan CG, Phillips LA, Su X, et al. Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia. Science. 2008;322(5906):1377-1380. doi:10.1126/science.1164266 Mullighan CG Phillips LA Su X Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia . Science . 2008 ; 322 ( 5906 ): 1377 - 1380 . doi: 10.1126/science.1164266 Open DOISearch in Google Scholar

14. Zhang H, Wang H, Qian X, et al. Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing. BMC Cancer. 2020;20(1):211. doi:10.1186/s12885-020-6709-7 Zhang H Wang H Qian X Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing . BMC Cancer . 2020 ; 20 ( 1 ): 211 . doi: 10.1186/s12885-020-6709-7 Open DOISearch in Google Scholar

15. Ueno H, Yoshida K, Shiozawa Y, et al. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2020;4(20):5165. doi:10.1182/bloodad-vances.2019001307 Ueno H Yoshida K Shiozawa Y Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia . Blood Adv . 2020 ; 4 ( 20 ): 5165 . doi: 10.1182/bloodad-vances.2019001307 Open DOISearch in Google Scholar

16. van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. doi:10.1038/sj.leu.2403202 van Dongen JJM Langerak AW Brüggemann M Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936 . Leukemia . 2003 ; 17 ( 12 ): 2257 - 2317 . doi: 10.1038/sj.leu.2403202 Open DOISearch in Google Scholar

17. Krstevska Bozhinovikj E, Matevska-Geshkovska N, Stojovska M, et al. Presence of Minimal Residual Disease Determined by Next-Generation Sequencing Is Not a Reliable Prognostic Biomarker in Children with Acute Lymphoblastic Leukemia. Leuk Lymphoma 2024 (submitted) doi:10.22541/au.172536128.83797266/v1 Krstevska Bozhinovikj E Matevska-Geshkovska N Stojovska M Presence of Minimal Residual Disease Determined by Next-Generation Sequencing Is Not a Reliable Prognostic Biomarker in Children with Acute Lymphoblastic Leukemia . Leuk Lymphoma 2024 (submitted) doi: 10.22541/au.172536128.83797266/v1 Open DOISearch in Google Scholar

18. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901-1928. doi:10.1038/sj.leu.240159 van Dongen JJ Macintyre EA Gabert JA Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia . Leukemia . 1999 ; 13 ( 12 ): 1901 - 1928 . doi: 10.1038/sj.leu.2401592 Open DOISearch in Google Scholar

19. ALL IC-BFM 2009 A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia; Available online: https://ascopubs.org/doi/suppl/10.1200/JCO.22.01760/suppl_file/protocol1_jco.22.01760.pdf (accessed 16.10.2024) ALL IC-BFM 2009 A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia ; Available online: https://ascopubs.org/doi/suppl/10.1200/JCO.22.01760/suppl_file/protocol1_jco.22.01760.pdf (accessed 16.10.2024). Search in Google Scholar

20. Stanulla M, Dagdan E, Zaliova M, et al. IKZF1p-lus Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J. Clin. Oncol. 2018;36(12):1240-1249. doi:10.1200/JCO.2017.74.3617 Stanulla M Dagdan E Zaliova M IKZF1p-lus Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia . J. Clin. Oncol . 2018 ; 36 ( 12 ): 1240 - 1249 . doi: 10.1200/JCO.2017.74.3617 Open DOISearch in Google Scholar

21. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165-1174. doi:10.1182/blood-2012-05-378943 Pui CH Mullighan CG Evans WE Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood . 2012 ; 120 ( 6 ): 1165 - 1174 . doi: 10.1182/blood-2012-05-378943 Open DOISearch in Google Scholar

22. Li B, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135(1):41-55. doi:10.1182/blood.2019002220 Li B Brady SW Ma X Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia . Blood . 2020 ; 135 ( 1 ): 41 - 55 . doi: 10.1182/blood.2019002220 Open DOISearch in Google Scholar

23. Oshima K, Khiabanian H, da Silva-Almeida AC, et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2016;113(40):11306-11311. doi:10.1073/pnas.1608420113 Oshima K Khiabanian H da Silva-Almeida AC Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia . Proc Natl Acad Sci U S A . 2016 ; 113 ( 40 ): 11306 - 11311 . doi: 10.1073/pnas.1608420113 Open DOISearch in Google Scholar

24. Sayyab S, Lundmark A, Larsson M, et al. Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia. Sci Rep. 2021;11(1):15988. doi:10.1038/s41598-021-95109-0 Sayyab S Lundmark A Larsson M Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia . Sci Rep . 2021 ; 11 ( 1 ): 15988 . doi: 10.1038/s41598-021-95109-0 Open DOISearch in Google Scholar

25. Malinowska-Ozdowy K, Frech C, Schönegger A, et al. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. Leukemia. 2015;29(8):1656-1667. doi:10.1038/leu.2015.107 Malinowska-Ozdowy K Frech C Schönegger A KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia . Leukemia . 2015 ; 29 ( 8 ): 1656 - 1667 . doi: 10.1038/leu.2015.107 Open DOISearch in Google Scholar

26. Zhu Y, Wang Z, Li Y, et al. The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies. Cancers. 2023;15(4):1219. doi:10.3390/cancers15041219 Zhu Y Wang Z Li Y The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies . Cancers . 2023 ; 15 ( 4 ): 1219 . doi: 10.3390/cancers15041219 Open DOISearch in Google Scholar

27. Ramírez-Komo JA, Delaney MA, Straign D, et al. Spontaneous loss of B lineage transcription factors leads to pre-B leukemia in Ebf1+/–Bcl-xLTg mice. Oncogenesis. 2017;6(7):e355-e355. doi:10.1038/oncsis.2017.55 Ramírez-Komo JA Delaney MA Straign D Spontaneous loss of B lineage transcription factors leads to pre-B leukemia in Ebf1+/–Bcl-xLTg mice . Oncogenesis . 2017 ; 6 ( 7 ): e355 - e355 . doi: 10.1038/oncsis.2017.55 Open DOISearch in Google Scholar

28. Yang JJ, Bhojwani D, Yang W, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008;112(10):4178-4183. doi:10.1182/blood-2008-06-165027 Yang JJ Bhojwani D Yang W Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia . Blood . 2008 ; 112 ( 10 ): 4178 - 4183 . doi: 10.1182/blood-2008-06-165027 Open DOISearch in Google Scholar

29. Li X, Lin S, Liao N, et al. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children’s leukemia group. Hematol. Oncol. 2024;42(3):e3265. doi:10.1002/hon.3265 Li X Lin S Liao N The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children’s leukemia group . Hematol. Oncol . 2024 ; 42 ( 3 ): e3265 . doi: 10.1002/hon.3265 Open DOISearch in Google Scholar

30. Park KJ, Kim IS. Clinically actionable mutations identified in Korean patients with high-risk acute lymphoblastic leukemia. Ann Oncol. 2018;29:viii370-viii371. doi:10.1093/annonc/mdy286.036 Park KJ Kim IS. Clinically actionable mutations identified in Korean patients with high-risk acute lymphoblastic leukemia . Ann Oncol . 2018 ; 29 : viii370 - viii371 . doi: 10.1093/annonc/mdy286.036 Open DOISearch in Google Scholar

31. Vervoort BMT, Butler M, Grünewald KJT, et al. IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia. Haematologica. Published online June 6, 2024. doi:10.3324/haematol.2023.284357 Vervoort BMT Butler M Grünewald KJT IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia . Haematologica. Published online June 6 , 2024 . doi: 10.3324/haematol.2023.284357 Open DOISearch in Google Scholar

32. Stanulla M, Cavé H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood. 2020;135(4):252-260. doi:10.1182/blood.2019000813 Stanulla M Cavé H Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood . 2020 ; 135 ( 4 ): 252 - 260 . doi: 10.1182/blood.2019000813 Open DOISearch in Google Scholar

33. Feng J, Guo Y, Yang W, et al. Childhood Acute B-Lineage Lymphoblastic Leukemia With CDKN2A/B Deletion Is a Distinct Entity With Adverse Genetic Features and Poor Clinical Outcomes. Front Oncol. 2022;12. doi:10.3389/fonc.2022.878098 Feng J Guo Y Yang W Childhood Acute B-Lineage Lymphoblastic Leukemia With CDKN2A/B Deletion Is a Distinct Entity With Adverse Genetic Features and Poor Clinical Outcomes . Front Oncol . 2022 ; 12 . doi: 10.3389/fonc.2022.878098 Open DOISearch in Google Scholar

34. Ampatzidou M, Papadhimitriou SI, Paisiou A, et al. The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols. Diagnostics. 2023;13(9):1589. doi:10.3390/diagnostics13091589 Ampatzidou M Papadhimitriou SI Paisiou A The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols . Diagnostics . 2023 ; 13 ( 9 ): 1589 . doi: 10.3390/diagnostics13091589 Open DOISearch in Google Scholar

35. Oshima K, Zhao J, Pérez-Durán P, et al. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nat Cancer. 2020;1(11):1113-1127. doi:10.1038/s43018-020-00124-1 Oshima K Zhao J Pérez-Durán P Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia . Nat Cancer . 2020 ; 1 ( 11 ): 1113 - 1127 . doi: 10.1038/s43018-020-00124-1 Open DOISearch in Google Scholar